Publication:
Development of [18F]ICMT-11 for Imaging Caspase-3/7 Activity during Therapy-Induced Apoptosis

Simple item page
dc.contributor.authorGarcía-Argüello, Segundo Francisco
dc.contributor.authorLopez-Lorenzo, Beatriz
dc.contributor.authorCornelissen, Bart
dc.contributor.authorSmith, Graham
dc.contributor.authoraffiliation[García-Argüello,SF] Centro de Investigaciones Médico-Sanitarias, Fundación General Universidad de Málaga, Málaga, Spain. [García-Argüello,SF] Grupo de Arteriosclerosis, Prevención Cardiovascular y Metabolismo, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain. [Lopez-Lorenzo,B] Biomedicina, Investigación Traslacional y Nuevas Tecnologías en Salud, Universidad de Málaga, Málaga, Spain. [Lopez-Lorenzo,B] BIONAND-Centro Andaluz de Nanomedicina y Biotecnología (Junta de Andalucía—Universidad de Málaga), Málaga, Spain. [Cornelissen,B; Smith,G] Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building, Oxford, UK.
dc.date.accessioned2024-02-12T19:46:54Z
dc.date.available2024-02-12T19:46:54Z
dc.date.issued2020-08-06
dc.description.abstractInsufficient apoptosis is a recognised hallmark of cancer. A strategy to quantitatively measure apoptosis in vivo would be of immense value in both drug discovery and routine patient management. The first irreversible step in the apoptosis cascade is activation of the "executioner" caspase-3 enzyme to commence cleavage of key structural proteins. One strategy to measure caspase-3 activity is Positron Emission Tomography using isatin-5-sulfonamide radiotracers. One such radiotracer is [18F]ICMT-11, which has progressed to clinical application. This review summarises the design and development process for [18F]ICMT-11, suggesting potential avenues for further innovation.
dc.identifier.doi10.3390/cancers12082191
dc.identifier.e-issn2072-6694es_ES
dc.identifier.journalCancerses_ES
dc.identifier.otherhttp://hdl.handle.net/10668/4148
dc.identifier.pubmedID32781531es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18090
dc.language.isoeng
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.publisherversionhttps://www.mdpi.com/2072-6694/12/8/2191/htmes
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectPositron emission tomography
dc.subjectApoptosis
dc.subjectCaspase-3
dc.subject[18F]ICMT-11
dc.subjectPyrimidoindolone
dc.subjectMichael acceptor
dc.subjectNeoplasms
dc.subjectIsatin
dc.subjectTomografía de emisión de positrones
dc.subjectCaspasa-3
dc.subjectNeoplasias
dc.subjectIsatina
dc.subject.meshCaspase 3
dc.subject.meshIsatin
dc.subject.meshPositron-Emission Tomography
dc.subject.meshApoptosis Inducing Factor
dc.subject.meshSulfonamides
dc.subject.meshNeoplasms
dc.subject.meshDrug Discovery
dc.subject.meshHumans
dc.titleDevelopment of [18F]ICMT-11 for Imaging Caspase-3/7 Activity during Therapy-Induced Apoptosis
dc.typereview article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isPublisherOfPublication30293a55-0e53-431f-ae8c-14ab01127be9
relation.isPublisherOfPublication.latestForDiscovery30293a55-0e53-431f-ae8c-14ab01127be9

Files

Collections

IBIMA-Plataforma BIONAND - Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (Andalucía)